what is melanotan: Frequently asked questions

Reduce your next dose by 50%—from 0.5mg to 0.25mg—and inject immediately before bed rather than during waking hours. Nausea from Melanotan II is mediated by MC4R activation in the hypothalamus and peaks 30–90 minutes post-injection. Taking the injection on an empty stomach amplifies the effect; injecting after a small meal or protein snack blunts the nausea response in most users. If nausea persists at 0.25mg, discontinue use—this indicates high MC4R sensitivity, and continuing risks hypotension and vomiting severe enough to require medical intervention.

Switch to Melanotan 1 (afamelanotide), which maintains MC1R-selective activity without significant MC4R binding. Melanotan 1 produces equivalent melanogenesis with negligible appetite suppression, erectile effects, or nausea, making it suitable for studies focused exclusively on pigmentation or photoprotection mechanisms. The trade-off is a shorter half-life requiring more frequent administration or continuous infusion to maintain receptor occupancy.

This is expected and reflects regional variation in melanocyte density and MC1R expression. The face, particularly the forehead, cheeks, and upper lip, contains higher melanocyte concentrations and responds more rapidly to MC1R agonism than the torso or limbs. Freckles and moles darken disproportionately because these areas already have elevated melanin production at baseline. There is no injection technique or dosing adjustment that equalizes pigmentation distribution—uneven darkening is an inherent feature of melanocortin-driven tanning. If cosmetic uniformity is the priority, Melanotan II is not the appropriate tool.

This is an on-target effect of MC4R activation, not a side effect. MC4R agonism in the hypothalamus and spinal cord increases dopaminergic signaling in neural pathways governing sexual arousal and erectile function. The effect is dose-dependent and more pronounced in male users, though increased libido is reported in both sexes. If the effect is unwanted or disruptive, reduce your dose by 50% or switch to Melanotan I (afamelanotide), which has minimal MC4R binding. Do not attempt to counteract the effect with phosphodiesterase-5 inhibitors (sildenafil, tadalafil)—this combination can produce prolonged erections lasting 4+ hours (priapism), a medical emergency requiring aspiration.

Refrigerate immediately and do not use if the vial was at room temperature for more than 12 hours. Peptide bonds and the lactam bridge structure undergo accelerated hydrolysis at temperatures above 8°C, and while the solution may appear unchanged, receptor binding affinity can decrease by 20–40% after prolonged ambient exposure. Studies on peptide stability show that cyclic peptides are particularly vulnerable to conformational shifts when thermal energy disrupts the constrained ring structure.

Nausea results from MC4R activation in the hypothalamus and area postrema. The chemoreceptor trigger zone in the brainstem. And typically resolves within 2–4 hours. Reducing the initial dose to 0.25 mg and administering in the evening before sleep allows the acute nausea phase to pass during rest. Gradual dose escalation over 7–10 days permits receptor desensitization and reduces the incidence of gastrointestinal side effects in subsequent doses.

No. Melanin synthesized via Melanotan II persists in keratinocytes for the duration of the epidermal turnover cycle—approximately 28–45 days depending on age and skin area. The tan will fade gradually as melanin-containing keratinocytes desquamate and are replaced by non-pigmented cells. The fade rate is identical to UV-induced tan loss. Stopping Melanotan II does not trigger rapid depigmentation or rebound lightening—you simply revert to your baseline pigmentation over 4–8 weeks as the melanin-laden cells shed naturally.

Verify injection technique, reconstitution sterility, and peptide storage conditions before assuming the compound is inactive. Individuals with Fitzpatrick skin type I and minimal baseline melanocyte activity may require 10–14 days to produce visible pigmentation, as tyrosinase upregulation and melanosome maturation follow a lag phase that varies with genetic melanin synthesis capacity. If no pigmentation appears after 14 days of consistent dosing, the peptide may have been denatured during storage or reconstitution, or the individual may have MC1R polymorphisms that reduce receptor responsiveness.